2019-07-16T09:43:20-05:00 2018-12-31 520982413 GROSS MENDELSOHN & ASSOCIATES PA 1801 PORTER STREET SUITE 500 BALTIMORE MD 21230 990 2018-01-01 954132414 CURESEARCH FOR CHILDREN'S CANCER CURE 2402352200 4600 EAST WEST HIGHWAY NO 600 BETHESDA MD 20814 KAY KOEHLER CEO 2402352200 2019-07-16 1 JAMES E CRISP P00025401 4106855512 2019-07-16 144.121.150.146 2019-07-16 09:43:16 ED P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 7ED660B1DA5B7572EB4EFB1F9341951127F9693C 2018 2020-03-31 21:24:44Z KAY KOEHLER 4600 EAST WEST HIGHWAY NO 600 BETHESDA MD 20814 4910224 0 X WWW.CURESEARCH.ORG X 1987 CA CURESEARCH FUNDS AND SUPPORTS CHIDLREN'S CANCER RESEARCH AND PROVIDES EDUCATION AND RESOURCES TO ALL THOSE AFFECTED BY CHILDREN'S CANCER. 14 14 29 180 0 4146 1796520 1870428 0 250000 188364 192460 2508583 2119366 4493467 4432254 1404136 1448146 0 0 2642196 1935245 0 0 670175 1137473 1167074 5183805 4550465 -690338 -118211 5314368 4782240 351872 217832 4962496 4564408 X CURESEARCH'S MISSION IS TO FUND AND SUPPORT TARGETED AND INNOVATIVE CANCER RESEARCH WITH MEASURABLE RESULTS, AND TO BE THE AUTHORITATIVE SOURCE OF INFORMATION AND RESOURCES FOR ALL THOSE AFFECTED BY CHILDREN'S CANCER.(SEE SCHEDULE O FOR CONTINUATION)CURESEARCH SUPPORTS CHILDHOOD CANCER RESEARCH AT ALL STAGES ALONG THE RESEARCH CONTINUUM, FROM FELLOWSHIPS THAT ACCELERATE THE CAREERS OF YOUNG RESEARCHERS TO MULTI-MILLION DOLLAR GRANTS THAT SUPPORT RESEARCH TEAMS DEVELOPING POTENTIAL NEW TREATMENTS, TO CLINICAL TRIAL AWARDS THAT ENABLE HOSPITALS TO ENROLL CHILDREN BEING TREATED TODAY. IT PROVIDES EDUCATIONAL RESOURCES TO PARENTS AND CAREGIVERS, INCLUDING PLAIN LANGUAGE INFORMATION ON DIAGNOSIS AND TREATMENT, PROCEDURAL VIDEOS, AND PARENT WEBINARS. CURESEARCH ALSO RAISES FUNDS THROUGH INDIVIDUALS, CORPORATIONS, PRIVATE FOUNDATIONS, AND SPECIAL EVENTS. 0 0 3194025 1448146 250000 CURESEARCH SUPPORTS RESEARCH EFFORTS TO IMPROVE TREATMENTS AND FIND CURES FOR CHILDREN'S CANCER. THROUGH COMPETITIVE GRANT MAKING INITIATIVES, CURESEARCH FUNDS RESEARCH TEAMS ACROSS THE COUNTRY THAT STUDY MORE THAN 13 TYPES OF CANCER IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH THE GOAL OF IMPROVING CURRENT TREATMENTS, DEVELOPING NEW THERAPIES, AND UNDERSTANDING THE BIOLOGY OF MORE PEDIATRIC CANCER DISEASE TYPES. CURESEARCH FUNDS RESEARCH AT ALL STAGES OF THE PIPELINE, INCLUDING BASIC SCIENCE, TRANSLATIONAL RESEARCH, CLINICAL TRIAL DEVELOPMENT, AND THE TESTING OF NEW CANCER THERAPIES. THIS RESEARCH IMPACTS OVER 14,900 CHILDREN DIAGNOSED WITH CANCER EACH YEAR WITH THE LONG-TERM GOAL OF DEVELOPING THERAPIES THAT CURE CHILDREN TODAY WITHOUT HARMING THEM TOMORROW. (SEE SCHEDULE O FOR CONTINUATION)CURESEARCH FUNDS CLINICAL TRIALS ACROSS THE COUNTRY. CLINICAL TRIALS ENSURE THAT CHILDREN WITH CANCER GET ACCESS TO THE BEST CURRENT TREATMENTS. THE DATA COLLECTED FROM CLINICAL TRIALS ENABLES RESEARCHERS TO ACHIEVE A BETTER UNDERSTANDING OF CANCER BIOLOGY AND GUIDES THE DEVELOPMENT OF NEW TREATMENTS AND TREATMENT PROTOCOLS. CLINICAL TRIALS ARE COSTLY FOR HOSPITALS, WHICH RELY ON SUPPORT FROM CURESEARCH AND OTHER ORGANIZATIONS TO BE ABLE TO PROVIDE TREATMENT FOR CHILDREN WITH CANCER. EACH YEAR, ALMOST 10,000 CHILDREN ARE ENROLLED IN CLINICAL TRIALS. IN ADDITION TO FUNDING RESEARCH, CURESEARCH ALSO PROVIDES INFORMATION AND RESOURCES TO PATIENTS AND FAMILIES. CURESEARCH RESOURCES INCLUDE CURESEARCH.ORG, AN ONLINE RESOURCE WITH PLAIN LANGUAGE INFORMATION ON DIAGNOSIS AND TREATMENT FOR CHILDREN?S CANCER; A LIBRARY OF PROCEDURE VIDEOS THAT DEMONSTRATE CANCER TREATMENTS FOR CHILDREN; AND WEBINARS AND GUIDES FOR PARENTS ON COPING WITH CANCER, FINDING COMMUNITY SUPPORT, AND REINTEGRATING A CHILD INTO SCHOOL AND SOCIAL ENVIRONMENTS. THESE RESOURCES AID ABOUT 28,500 INDIVIDUALS EACH YEAR. 3194025 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 19 0 1 29 1 0 0 0 0 0 0 0 0 0 0 X 14 14 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AK AZ AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X X MANAGEMENT 2402352200 4600 EAST WEST HIGHWAY BETHESDA MD 20814 STUART SIEGEL MD CHAIR 1.00 X X 0 0 0 MICHAEL R MILLER ESQUIRE SECRETARY 1.00 X X 0 0 0 WALTER B ROSE TREASURER 1.00 X X 0 0 0 SHARI COLLIER DIRECTOR 1.00 X 0 0 0 JARED D BRANCAZIO WMS DIRECTOR 1.00 X 0 0 0 CASON CARTER DIRECTOR 1.00 X 0 0 0 MIKE CARTER DIRECTOR 1.00 X 0 0 0 PAULA CARTER DIRECTOR 1.00 X 0 0 0 ANNIE GOULD DIRECTOR 1.00 X 0 0 0 CARLEEN HAWN DIRECTOR 1.00 X 0 0 0 RICHARD J O'REILLY MD DIRECTOR 1.00 X 0 0 0 MATT KELLY DIRECTOR 1.00 X 0 0 0 SAMUEL C BLACKMAN MD PHD DIRECTOR 1.00 X 0 0 0 KATHY WANNER DIRECTOR 1.00 X 0 0 0 RICHARD PAYNE EMERITUS DIRECTOR 1.00 X 0 0 0 MARY PAYNE EMERITUS DIRECTOR 1.00 X 0 0 0 KAY KOEHLER PRESIDENT / CEO 40.00 X 260007 0 9594 KATHARINE BURKE COO & VP FINANCE 40.00 X 188254 0 10009 TIFFANI COPELAND VP CAMPAIGN DEVELOPMENT AND COMMUNICATIONS 40.00 X 126386 0 5174 LAURA THRALL FORMER PRESIDENT / CEO 40.00 X 106246 0 3049 680893 0 27826 4 1 1 0 0 1870428 17219 1870428 SERVICE CONTRACT REVENUE 541700 250000 250000 250000 107185 107185 479126 393851 85275 85275 85275 2202694 84119 2118575 2118575 MISCELLANEOUS REVENUE 541700 791 791 791 4432254 250000 0 2311826 1085247 1085247 362899 362899 467862 252238 210232 5392 1231698 778975 121095 331628 13414 9192 160 4062 99751 62205 15180 22366 122520 74524 23431 24565 60000 60000 84490 84490 20473 20473 127631 86447 20105 21079 68510 41672 13102 13736 145960 88782 27914 29264 160921 97882 30775 32264 111396 22211 14364 74821 53076 37261 2789 13026 34858 21203 6666 6989 57858 35193 11065 11600 PUBLIC RELATIONS 118435 102690 8510 7235 BANK FEES 62422 1945 60477 DUES AND SUBSCRIPTIONS 33971 20663 6497 6811 REGISTRATIONS, PERMITS 11696 7114 2237 2345 15377 7627 5235 2515 4550465 3194025 686265 670175 455098 164739 201178 378284 143138 121641 220474 462976 33675 21465 272687 252175 55371 20512 4159682 3572667 45752 39956 5314368 4782240 226950 147795 42070 33034 82852 37003 351872 217832 X 416635 1396519 3045861 1667889 1500000 1500000 4962496 4564408 5314368 4782240 -118211 -279877 0 X X 0 1 X 1 0 X 2132029 3341030 2598912 1796520 1870428 11738919 2132029 3341030 2598912 1796520 1870428 11738919 2050979 9687940 116282 173280 158815 133702 107185 689264 41814 35 3385 36875 791 82900 12511083 14785252 0.77430 0.80780 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2014 AMOUNT: $ 41,814. 2015 AMOUNT: $ 35. 2016 AMOUNT: $ 3,385. 2017 AMOUNT: $ 36,875. 2018 AMOUNT: $ 791. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2152233 -113850 100000 1938383 2969834 277370 1094971 2152233 2969455 146915 146536 2969834 3095943 -25488 101000 2969455 2982976 165038 52071 3095943 0.77380 0.22620 0 0 171695 151183 20512 82447 82447 0 18545 18545 0 20512 DEFERRED RENT 37003 37003 X 4131904 -279877 -279877 4411781 20473 20473 4432254 4529992 0 4529992 20473 20473 4550465 PART V, LINE 4: DONOR RESTRICTED ENDOWMENT FUNDS HAVE BEEN ESTABLISHED TO ADVANCE PEDIATRIC CANCER RESEARCH BY DISEASE, BY MEDICAL DISCIPLINE, OR THROUGH RESEARCH FELLOWSHIPS. PART X, LINE 2: IN ACCORDANCE WITH FIN 48 (ASC 740), INCOME TAXES, MANAGEMENT EVALUATED ITS ACTIVITIES AND DETERMINED THAT CURESEARCH HAD TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO OR DISCLOSURE IN THE FINANCIAL STATEMENTS TO COMPLY WITH THE PROVISIONS OF THE ACCOUNTING STANDARD. IN GENERAL, THE ORGANIZATION'S FEDERAL EXEMPT ORGANIZATION TAX RETURNS ARE SUBJECT TO EXAMINATION BY THE IRS, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THE RETURNS ARE FILED. 1 EUROPE (INCLUDING ICELAND & GREENLAND, ALBANIA, ANDORRA, AUSTRIA, BELGIUM) 0 0 GRANT FOR CANCER RESEARCH GRANT FOR CANCER RESEARCH 362899 0 0 0 0 0 0 362899 0 362899 UNITED KINGDOM THERAPEUTIC 362899 WIRE TRANSFER 1 0 0 0 0 0 0 PART I, LINE 2: PROGRESS REPORTS ARE MONITORED WALK/RUN EVENT 2202694 2202694 13180 7975 24683 38281 2202694 2202694 13180 7975 24683 38281 84119 2118575 1 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BP412 BOSTON MA 022155450 422263040 501 (C) (3) 75000 THERAPEUTIC STANFORD UNIVERSITY 3712 PORTER DRIVE PALO ALTO CA 94304 941156365 501 (C) (3) 167781 THERAPEUTIC MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE BOX 701 NEW YORK NY 10065 131924236 501 (C) (3) 346045 THERAPEUTIC UNIVERSITY OF PENNSYLVANIA 3400 CIVIC CENTER BLVD PHILADELPHIA PA 191045156 231352685 501 (C) (3) 75000 THERAPEUTIC YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501 (C) (3) 317749 THERAPEUTIC 5 PART I, LINE 2: CURESEARCH'S MANAGEMENT WILL REQUEST PERIODIC REPORTS AND STATUS UPDATES OF ITS GRANT AWARDS THROUGHOUT THE YEAR. X X X 0 0 0 0 0 0 0 0 0 KAY KOEHLER PRESIDENT / CEO 260007 0 0 0 0 0 3385 0 6209 0 269601 0 0 0 KATHARINE BURKE COO & VP FINANCE 188254 0 0 0 0 0 3800 0 6209 0 198263 0 0 0 LAURA THRALL FORMER PRESIDENT / CEO 106246 0 0 0 0 0 1497 0 1552 0 109295 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 THE MEMBERSHIP OF CURESEARCH'S BOARD OF DIRECTORS INCLUDES MIKE, PAULA AND CASON CARTER (HUSBAND, WIFE AND SON). IT ALSO INCLUDES RICHARD PAYNE AND MARY PAYNE (HUSBAND AND WIFE). FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION RETAINS AN OUTSIDE CPA TO PREPARE THE IRS FORM 990. PRIOR TO FILING, THE COMPLETED RETURN IS REVIEWED IN DETAIL BY THE CEO/PRESIDENT AND PRESENTED TO THE EXECUTIVE COMMITTEE OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR, ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES ARE PROVIDED WITH THE CONFLICT OF INTEREST POLICY FOR REVIEW. ALL NEW EMPLOYEES ARE REQUIRED TO READ THE CONFLICT OF INTEREST POLICY AND SIGN IT AS PART OF THEIR ORIENTATION. THE POLICY REQUIRES THAT ANYONE WHO KNOWS OF AN ACTUAL OR PERCEIVED CONFLICT OF INTEREST MUST REPORT IT. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION OF THE CEO WAS DETERMINED BY THE BOARD CHAIR AFTER CONSIDERATION OF COMPATIBILITY DATA PROVIDED BY THE HUMAN RESOURCES DEPARTMENT. THE BOARD APPROVED THE BOARD CHAIR'S RECOMMENDATION. FORM 990, PART VI, SECTION C, LINE 19 CURESEARCH'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. CURESEARCH'S FINANCIAL STATEMENTS AND FORM 990S ARE AVAILABLE ON ITS WEBSITE - CURESEARCH.ORG 990 PART VII, LINE 2C PROCESS HAS NOT CHANGED FROM PRIOR YEAR